In short
This article discusses clinical trials investigating the use of Allogenic Sclerocorneal Limbus Stem-Derived Adult Limbal Cells, Ex-Vivo Expanded, in treating severe corneal ulcers. These advanced therapy trials aim to evaluate the safety, feasibility, and effectiveness of nanostructured artificial corneas for patients who have not responded to conventional treatments. The studies focus on regenerating damaged corneal tissue and improving visual outcomes for those with challenging eye conditions.
At a glance
- Treatment
- Allogenic Sclerocorneal Limbus Stem-Derived Adult Limbal Cells and Allogenic Corneal-Derived Adult Keratocytes, Ex-Vivo Expanded
- Administration
- Implantation of nanostructured artificial cornea
- Target Condition
- Severe corneal ulcers refractory to conventional treatment
- Primary Objectives
- Evaluate safety, feasibility, and clinical efficacy
- Key Inclusion Criteria
- Adults with severe corneal ulcers, disease duration ≥3-6 weeks, no active ocular infection
- Key Exclusion Criteria
- Pregnancy, active neoplasia, recent participation in other clinical trials
- Primary Endpoints
- Adverse events, graft conditions, infection signs, corneal vascularization
- Secondary Endpoints
- Corneal regeneration, visual acuity, quality of life, corneal surface characterization
What is this treatment?
ALLOGENIC SCLEROCORNEAL LIMBUS STEM-DERIVED ADULT LIMBAL CELLS, EX-VIVO EXPANDED is an advanced therapy medicinal product being studied for the treatment of severe corneal ulcers. This innovative treatment is also known by other names, including:
- NANOULCOR
- Nanostructured fibrin-agarose artificial cornea model
- Human nanostructured artificial cornea
This treatment is a type of living tissue equivalent, which means it's designed to mimic and replace damaged corneal tissue.
How does it work?
This treatment works by using specially prepared cells to help regenerate damaged corneal tissue. It combines two types of cells:
- Allogenic sclerocorneal limbus stem-derived adult limbal cells: These are stem cells taken from the limbus (the border between the cornea and the white part of the eye) of a donor. They are grown (expanded) in a laboratory.
- Allogenic corneal-derived adult keratocytes: These are cells from the cornea of a donor, also expanded in the lab.
These cells are combined with a special biological matrix to create a living tissue equivalent that can be implanted into the patient's eye. The goal is for this artificial cornea to integrate with the patient's own tissue and help heal severe corneal damage.
What conditions does it treat?
This treatment is being studied for patients with severe corneal ulcers that haven't responded to conventional treatments. Specifically, it may help with:
- Corneal trophic ulcers: These are persistent sores on the cornea that don't heal properly.
- Sequelae of previous ulcers: This refers to complications or after-effects of past corneal ulcers, such as:
- Stromal thinning (thinning of the middle layer of the cornea)
- Corneal fibrosis (scarring)
- These conditions may or may not be associated with limbal insufficiency (a lack of stem cells in the limbus) in the affected eye.
Current clinical trials
There are currently two clinical trials studying this treatment:
- A Phase IIb trial called NANOULCOR, which aims to evaluate the clinical efficacy of the treatment in patients with severe corneal ulcers.
- A multicenter trial to assess the safety, feasibility, and evidence of clinical efficacy in patients with advanced corneal trophic ulcers that haven't responded to conventional treatments.
Potential benefits
The researchers are hoping this treatment will provide several benefits for patients:
- Regeneration of the damaged corneal tissue
- Reduction in healing time for corneal ulcers
- Improvement in visual acuity (sharpness of vision)
- Reduction in corneal complications
- Improvement in the patient's quality of life
Who is eligible for this treatment?
While the exact eligibility criteria may vary between clinical trials, generally, patients who might be eligible for this treatment include:
- Adults (18 years or older) with severe corneal ulcers that haven't responded to conventional treatments for at least 3-6 weeks
- Patients with corneal thinning, clouding, or other sequelae from previous severe ulcers
- Those with corneal damage that doesn't extend to the deepest layer (Descemet's membrane)
However, patients with certain conditions may not be eligible, including those with:
- Active eye infections
- Certain systemic diseases or infections
- Pregnancy or breastfeeding
- Recent participation in other clinical trials
Safety considerations
As with any new treatment, safety is a primary concern. The clinical trials are designed to carefully monitor for any adverse effects. Some key safety aspects being evaluated include:
- The occurrence of adverse events and severe adverse events related to the treatment
- The condition of the implanted artificial cornea (whether it maintains its integrity, survives, or is reabsorbed)
- Any signs of local, regional, or systemic infection
- The development of new blood vessels in the cornea (induced corneal vascularization)
It's important to note that this treatment is still in the clinical trial phase. More research is needed to fully understand its effectiveness and long-term safety profile.